198. The usefulness of sFlt-1/PlGF on late onset preeclampsia

Abstract

Introduction Endothelial cell dysfunction is thought to be the main pathophysiological condition of preeclampsia(PE). Increased production of soluble Fms-like tyrosinekinase-1(sFlt-1) and decrease on placental growth factor(PlGF) in PE patients lead to be an established biomarker for early onset PE at 1st trimester. Other hand, the utility of this angiogenic biomarker for predicting late onset PE has not been clarified. Objectives We performed this study to assess the usefulness of sFlt-1/PlGF at late weeks of gestation as a predictive biomarker for late-onset PE. Methods This is a single-center, retrospective cohort study conducted between April 2016 and June 2017 using the records of the Department of Obstetrics at Perinatal Medical Center of TOYOTA Memorial Hospital, Japan. We examined this biomarker for patients who had or were expected to develop PE. We defined sFlt-1/PlGF Results 36 patients were included in the study and the mean age was 31.5 years old and median gestational weeks at blood sampling were 35 weeks of gestation. High risk group included 23 patients, middle risk group included 7 patients and low risk group included 6 patients. The rates of PE in each group were 73.9%, 28.5% and 16.7%. The rate of Cesarean section was significantly higher in high risk group compared with low risk group (70.0% vs 16.7%, p = 0.018). Gestational age at delivery was much shorter in high risk group than intermediate (35w vs 37w p = 0.003) and low risk group (35w vs 39w p = 0.002). Discussion sFlt-1/PlGF at late weeks of gestation can be useful on predicting late onset PE. Further clinical research is needed to make this biomarker established.